Frontier Medicines Secures $80 Million for Clinical-Stage Pipeline

Frontier Medicines, a precision medicine company, has successfully closed an oversubscribed $80 million Series C financing round. This funding will propel the progress of their clinical-stage pipeline, with a focus on the first-in-class direct dual inhibitor, FMC-376, targeting KRASG12C cancers. The financing was co-led by Deerfield Management Company and Droia Ventures, with participation from strategic investor Galapagos NV and other key investors. This milestone marks a significant step towards advancing transformative therapies for patients with otherwise undruggable targets. The Phase 1/2 PROSPER trial has already dosed its first participant, showcasing the potential of FMC-376 to overcome resistance mechanisms and improve patient outcomes. With a robust data set and promising preclinical results, Frontier Medicines is on track to deliver innovative precision medicines for patients in need.